Daniel Emil Levy

This inventor holds 16 USPTO granted patents and 18 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Ptc Therapeutics, Inc., Signpath Pharma, Inc., Johns Hopkins University. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Emil Levy. Retrieved from https://idiyas.com/inventor/daniel-emil-levy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 18)

% Patents Active = 93.8

CIPO Patents = 3 (Patent Applications = 12)

EPO Patents = 4 (Patent Applications = 12)

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 44(Granted Patents)

Company Filing History:

7 out of 186

Ptc Therapeutics, Inc.

patents

4 out of 25

Signpath Pharma, Inc.

patents

2 out of 3,798

Johns Hopkins University

patents

4. 1 out of 1

Allosteros Therapeutics, Inc.

6. 1 out of 834,453

Other

patents

Years Active: 2018-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12617809 - Cardioprotective lipid and method of use (2026-05-05),

2. 12534460 - LSD salt crystal forms (2026-01-27),

3. 12325706 - Polymorphic form of sepiapterin (2025-06-10),

4. 12269829 - Polymorphs of sepiapterin and salts thereof (2025-04-08),

5. 12213982 - Pharmaceutical compositions comprising sepiapterin and uses thereof (2025-02-04),

6. 11773097 - Polymorphs of sepiapterin and salts thereof (2023-10-03),

7. 11752154 - Pharmaceutical compositions comprising sepiapterin and uses thereof (2023-09-12),

8. 11746119 - Cardiopathy-reducing phosphodiester lipids (2023-09-05),

9. 11643424 - Cardiopathy-reducing phosphodiester lipids (2023-05-09),

10. 11325908 - CaMKII inhibitors and uses thereof (2022-05-10),

11. 11130760 - Polymorphic form of sepiapterin (2021-09-28),

12. 11072614 - Polymorphs of sepiapterin and salts thereof (2021-07-27),

13. 10975111 - Cardiopathy-reducing phosphodiester lipids (2021-04-13),

14. 10759792 - CaMKII inhibitors and uses thereof (2020-09-01),

15. 10081633 - Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof (2018-09-25),

Title: The Innovations of Daniel Emil Levy

Introduction

Daniel Emil Levy is a prominent inventor based in San Mateo, California. He holds a total of 14 patents, showcasing his significant contributions to the field of pharmaceuticals. His work primarily focuses on the development of innovative treatments for diseases associated with low intracellular BH4 levels.

Latest Patents

Among his latest patents is the "Polymorphic form of sepiapterin." This patent discloses a crystalline form of sepiapterin, along with a method for preparing this crystalline form. It also includes pharmaceutical compositions containing the crystalline form and a method for treating patients with diseases linked to low intracellular BH4 levels. Another notable patent is "Polymorphs of sepiapterin and salts thereof." This patent details various crystalline forms of sepiapterin free base and their pharmaceutical applications. Sepiapterin is particularly useful in treating conditions such as phenylketonuria.

Career Highlights

Daniel has worked with several notable companies, including PTC Therapeutics, Inc. and Signpath Pharma, Inc. His experience in these organizations has allowed him to advance his research and development efforts in the pharmaceutical industry.

Collaborations

Throughout his career, Daniel has collaborated with esteemed colleagues such as James D. McChesney and Annie Bouchard. These partnerships have contributed to the success of his innovative projects.

Conclusion

Daniel Emil Levy's work in the field of pharmaceuticals has led to significant advancements in treatments for various diseases. His patents reflect his dedication to improving patient care through innovative solutions.

Profile summary based on public USPTO records.